Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, improving outcomes for many patients. However, toxicities termed immune-related adverse events (irAEs) are limitations of these revolutionary treatments. These irAEs may resolve with treatment or ICI cessation (acute) or persist...
Saved in:
Main Authors: | Douglas B Johnson, Kylie Fletcher |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/12/7/e008591.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
by: Andrew L Mammen, et al.
Published: (2021-07-01) -
Establishment of an animal model of immune‐related adverse events induced by immune checkpoint inhibitors
by: Yuan Meng, et al.
Published: (2024-07-01) -
Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
by: Yan Xiao, et al.
Published: (2020-01-01) -
Endoscopic findings of immune checkpoint inhibitor-related gastrointestinal adverse events
by: Min Kyu Kim, et al.
Published: (2024-11-01) -
Enteritis of the ileal conduit as an adverse event related to immune checkpoint inhibitor use
by: Ko Kobayashi, et al.
Published: (2025-01-01)